In this episode, 'Epcoritamab in RRFL: Efficacy Data, Administration Considerations, and the Pharmacist's Operational Role,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions:
BCMA ADC belantamab added to DRd shows striking MRD negativity in early myeloma trials, but eye toxicity and access shape frontline use.
Cepheus data shows durable 6‑year control with DVRd, prompting new counseling and tailored dosing for frail, transplant‑ineligible myeloma patients.
This episode, titled 'What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical question:
In 'From Data to Practice: Interpreting inMIND Trial Results and the Role of Tafasitamab in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical questions
Experts debate quadruplet myeloma therapy, MRD-guided de-escalation, and risk-adapted intensification—plus how payers may respond.
Experts weigh quadruplet vs triplet myeloma therapy, tailoring to frailty and clots, and push early CAR-T/BCMA options for high-risk patients.
The panelists examined the significant progress made in frontline multiple myeloma treatment while emphasizing that true satisfaction will only come when more patients achieve a durable cure and can transition off maintenance therapy entirely, identifying MRD-guided treatment discontinuation as one of the most promising pathways toward that goal.
Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles.
In this episode, 'Operationalizing RRFL Care: Sequencing Therapies, Managing REMS, and the Role of R² in Practice,' the pharmacist Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions: 1. From a pharmacy operations standpoint, how do you characterize the current treatment landscape for relapsed or refractory follicular lymphoma (RRFL), and how has the growing number of available agents affected formulary management and operational planning at your institution? 2. Lenalidomide plus rituximab has been a commonly used combination in RRFL. How have you positioned this regimen in your own practice, and what have been its strengths and limitations in your experience?
Welcome back to another AJMC Insights series. In this episode titled, 'Setting the Stage: Treatment Selection and Eligibility in Follicular Lymphoma,' Ryan Haumschild, PharmD, MS, MBA, CPEL led the conversation about the following questions: 1. What are the first-line treatment options in follicular lymphoma? 2. When are you considering a patient eligible for later lines of therapy?
How payers curb inappropriate ATTR-CM therapy use with better scans, prior auth, real-world outcomes, and telemedicine to speed access.
Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies.
Real-world evidence and claims data compare amyloidosis therapies, linking outcomes and symptom burden to total cost of care.
In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.
Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.
Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival.
Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.
Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.
Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.
This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.
Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.
Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for non-small cell lung cancer.
Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.
Explore the significance of patient-reported outcomes in cancer treatment, highlighting the benefits of zongertinib and its impact on quality of life.
Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting its potential as a first-line treatment.
Discover the latest insights on Zongertinib's efficacy and safety for HER2-mutant non-small cell lung cancer, promising new treatment options.
Explore the differences between emerging HER2-targeted TKIs, Zongertinib and Seviberatinib, and their therapeutic implications in cancer treatment.
